Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PDI and Polymedco CDP Jointly Announce US Commercial Licensing Agreement

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
Polymedco to commercialize PDI’s diagnostic blood test that assesses an individual’s risk of CRC.

Phenomenome Discoveries Inc. and Polymedco Cancer Diagnostic Products LLC. have announced a commercial licensing agreement for the US market, providing rights to Polymedco to commercialize PDI’s diagnostic blood test that assesses an individual’s risk of colorectal cancer (“CRC”).

Using patented technology, PDI has discovered that approximately nine out of ten patients with CRC are deficient in novel anti-cancer and anti-inflammatory metabolites in their blood.

PDI has developed a convenient blood test assayed by triple quad mass spectrometry that can detect this deficiency.

PDI’s blood test is a simple non-invasive means of identifying individuals with increased risk of CRC. This blood test is expected to significantly improve CRC screening compliance.

On May 18, 2012 PDI presented results from a landmark multi-site, six thousand subject clinical trial evaluating the performance of the CRC test at the Digestive Disease Week (DDW) meeting in San Diego in which the blood test was found to detect over 85% of early stage CRC.

DDW is the largest and most prestigious meeting in the world for GI professionals. Every year it attracts approximately 16,000 physicians, researchers and academics from around the world.

“We are extremely pleased to be working with Polymedco to commercialize this test in the US market,” said John Hyshka, PDI’s Chief Financial and Operating Officer, “PDI has a number of similar products that are nearing market launch, and Polymedco’s unparalleled expertise as a world-leader in marketing and distributing non-invasive colorectal cancer screening products is very valuable.”

Dr. Dayan Goodenowe, PDI’s President and CEO, says “Polymedco’s proficiency has enabled us to exceed our goals and timelines around making this test available in the US. A month ago, we jointly submitted an application for FDA premarket review, and we look forward to receiving approval and moving ahead with our shared commercialization strategy.”

“We are excited about this new alliance with Phenomenome Discoveries. This new non-invasive technology adds to our cancer testing portfolio of market leading tests. We believe that this test will facilitate the screening of more patients annually for colorectal cancer. Increased screening rates will detect more cancers at an earlier stage, resulting in more lives saved,” said Drew Cervasio, President of Polymedco Cancer Diagnostic Products.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Rapid Retrieval of Live, Infectious Pathogens from Clinical Samples
An engineered pathogen-binding protein enables rapid isolation of infectious bacteria from joint fluids and accelerates their identification.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!